Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagnetisMM-7
jRCT2031220060Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2022
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Elranatamab with Lenalidomide (2 arms). Primary endpoint: Progression-free survival. Started Jun 2022; status: active, not recruiting.
02
Drugs
elranatamablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031220060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220060.